

James P Spiers

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8442802/james-p-spiers-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39
papers

935
citations

16
h-index

30
g-index

39
ext. papers

1,021
ext. citations

5.3
avg, IF

3.99
L-index

#	Paper	IF	Citations
39	New pharmacotherapy for heart failure with reduced ejection fraction. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 405-414	2.5	4
38	Protective effects of intermedin/adrenomedullin-2 in a cellular model of human pulmonary arterial hypertension. <i>Peptides</i> , 2020 , 126, 170267	3.8	4
37	Hypoxia modulates protein phosphatase 2A through HIF-1 α dependent and independent mechanisms in human aortic smooth muscle cells and ventricular cardiomyocytes. <i>British Journal of Pharmacology</i> , 2019 , 176, 1745-1763	8.6	6
36	Regulation of the phosphoprotein phosphatase 2A system and its modulation during oxidative stress: A potential therapeutic target?. <i>Pharmacology & Therapeutics</i> , 2019 , 198, 68-89	13.9	15
35	The role of PP2A in an inflammatory induced increase in Brain Microvascular Permeability. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, OR10-1	0	
34	Protein phosphatase 2A regulation of markers of extracellular matrix remodelling in hepatocellular carcinoma cells: functional consequences for tumour invasion. <i>British Journal of Pharmacology</i> , 2017 , 174, 1116-1130	8.6	16
33	Postprandial adiponectin and gelatinase response to a high-fat versus an isoenergetic low-fat meal in lean, healthy men. <i>Nutrition</i> , 2015 , 31, 863-70	4.8	12
32	Differential interactions of antiretroviral agents with LXR, ER and GR nuclear receptors: potential contributing factors to adverse events. <i>British Journal of Pharmacology</i> , 2014 , 171, 480-97	8.6	6
31	HIV-1 Tat clade-specific cytokine induction in monocytes/macrophages is not evidenced in total or V β V γ T lymphocytes. <i>Aids</i> , 2014 , 28, 131-3	3.5	1
30	The relationship between the MMP system, adrenoceptors and phosphoprotein phosphatases. <i>British Journal of Pharmacology</i> , 2012 , 166, 1225-43	8.6	23
29	Okadaic acid induces matrix metalloproteinase-9 expression in fibroblasts: crosstalk between protein phosphatase inhibition and β adrenoceptor signalling. <i>British Journal of Pharmacology</i> , 2012 , 165, 274-88	8.6	9
28	Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide. <i>Clinical Therapeutics</i> , 2012 , 34, 91-100	3.5	26
27	Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients. <i>Antiviral Therapy</i> , 2011 , 16, 1237-47	1.6	7
26	Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR112 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 55, 536-49	3.1	59
25	A primer on the mechanics of P-glycoprotein the multidrug transporter. <i>Pharmacological Research</i> , 2007 , 55, 1-15	10.2	154
24	Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. <i>International Journal of Clinical Practice</i> , 2007 , 61, 611-21	2.9	28
23	Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. <i>Journal of Human Hypertension</i> , 2007 , 21, 861-7	2.6	49

22	Protection of cardiomyocyte function by propofol during simulated ischemia is associated with a direct action to reduce pro-oxidant activity. <i>Journal of Molecular and Cellular Cardiology</i> , 2007 , 42, 600-8	5.8	20
21	Adrenoceptor blockade alters plasma gelatinase activity in patients with heart failure and MMP-9 promoter activity in a human cell line (ECV304). <i>Pharmacological Research</i> , 2006 , 54, 57-64	10.2	12
20	Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects. <i>Journal of Human Hypertension</i> , 2006 , 20, 867-73	2.6	63
19	Aging is associated with increased matrix metalloproteinase-2 activity in the human aorta. <i>American Journal of Hypertension</i> , 2005 , 18, 504-9	2.3	40
18	Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade. <i>Journal of Hypertension</i> , 2005 , 23, 1717-24	1.9	38
17	Neuropeptide Y Y(1) receptor regulates protein turnover and constitutive gene expression in hypertrophying cardiomyocytes. <i>European Journal of Pharmacology</i> , 2002 , 441, 23-34	5.3	17
16	St Johns wort increases expression of P-glycoprotein: implications for drug interactions. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 75-82	3.8	195
15	Myocardial expression of the endothelin system in endotoxin-treated rats. <i>Journal of Cardiovascular Pharmacology</i> , 2001 , 38, 259-67	3.1	3
14	Inotropic response to endothelin-1, isoprenaline and calcium in cardiomyocytes isolated from endotoxin treated rats: effects of ethyl-isothioureia and dexamethasone. <i>British Journal of Pharmacology</i> , 2000 , 130, 1275-82	8.6	6
13	Positive effect of bumetanide on contractile activity of ventricular cardiomyocytes. <i>European Journal of Pharmacology</i> , 2000 , 400, 43-50	5.3	4
12	Endothelin(A) receptor subtype mediates endothelin-induced contractility in left ventricular cardiomyocytes isolated from rabbit myocardium. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2000 , 294, 1047-52	4.7	14
11	Stimulation of L-type Ca ²⁺ current by the endothelin receptor A-selective antagonist, BQ-123 in ventricular cardiomyocytes isolated from the rabbit myocardium. <i>Biochemical Pharmacology</i> , 1998 , 55, 897-902	6	6
10	Receptor-mediated effects of endothelin on the L-type Ca ⁺⁺ current in ventricular cardiomyocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1998 , 286, 662-9	4.7	8
9	Inhibition of the acetylcholine-activated potassium current by endothelin-1 in atrial cardiomyocytes. <i>European Heart Journal</i> , 1997 , 18, 354-354	9.5	
8	Endothelin-1 mediated inhibition of the acetylcholine-activated potassium current from rabbit isolated atrial cardiomyocytes. <i>British Journal of Pharmacology</i> , 1996 , 119, 1427-37	8.6	5
7	Dual effects of endothelin-1 on the L-type Ca ²⁺ current in ventricular cardiomyocytes. <i>European Journal of Pharmacology</i> , 1996 , 308, 351-5	5.3	17
6	Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters. <i>Cardiovascular Drugs and Therapy</i> , 1996 , 10, 573-80	3.9	2
5	Evaluation of non-invasive blood pressure measurement by the Finapres method at rest and during dynamic exercise in subjects with cardiovascular insufficiency. <i>Clinical Autonomic Research</i> , 1994 , 4, 49-56	4.3	24

4	Time and frequency domain assessment of heart rate variability: a theoretical and clinical appreciation. <i>Clinical Autonomic Research</i> , 1993 , 3, 145-58	4.3	29
3	Duration of action and effect on baroreflex function of the anti-arrhythmic alpha 1 antagonist UK-52,046. <i>Journal of Pharmacy and Pharmacology</i> , 1991 , 43, 70-2	4.8	1
2	UK-52,046 (a novel alpha 1-adrenoceptor antagonist) and the role of alpha-adrenoceptor stimulation and blockade on atrioventricular conduction. <i>Journal of Cardiovascular Pharmacology</i> , 1990 , 16, 824-30	3.1	3
1	Acute and chronic effects of rilmenidine on baroreflex function in conscious dogs. <i>European Journal of Pharmacology</i> , 1990 , 181, 235-40	5.3	9